Pharmaceutical business development has never been more active — or more complex. With many large and mid-size pharma companies facing revenue gaps as blockbuster patents expire, external business development has become the primary engine of pipeline replenishment. According to EvaluatePharma, by 2028 the industry faces over $200 billion in cumulative revenue exposure from patent cliffs, making BD not just a growth strategy but a survival imperative.
Against that backdrop, BD teams are running harder with headcounts that have not expanded to match deal volume. The typical pharma BD group manages a portfolio of early-stage prospect relationships, several active due diligence tracks, and ongoing post-deal integration monitoring — simultaneously. The administrative weight of that workload is significant, and when it lands on the BD professionals themselves, deal quality and velocity both suffer.
Virtual assistants (VAs) with pharmaceutical industry backgrounds are stepping into the operational gap.
Managing the Licensing Deal Pipeline
A mature pharma BD function maintains a living pipeline of prospect relationships at various stages — from initial scientific awareness through to term sheet negotiation. Each entry in that pipeline requires regular activity: research updates, contact record maintenance, meeting follow-up, and competitive intelligence that might elevate or deprioritize a target.
VAs can own the administrative upkeep of the BD pipeline within CRM systems. They can research company milestones, monitor regulatory submissions, track clinical trial updates via ClinicalTrials.gov, and ensure that BD leads receive timely briefings on accounts that warrant re-engagement. This kind of pipeline intelligence maintenance is time-consuming when done manually; a skilled VA can systematize it and make it a continuous process rather than a pre-meeting scramble.
Due Diligence Operations
Pharmaceutical due diligence is extraordinarily document-intensive. A typical licensing due diligence process involves hundreds of scientific, regulatory, financial, and legal documents moving between the target company and the acquirer. BD teams without dedicated operational support frequently find themselves managing data room logistics at the same time they are trying to evaluate the underlying science.
VAs can manage the document management layer of due diligence: organizing virtual data room structures, tracking document request completion, coordinating internal SME reviews with regulatory, clinical, and IP teams, and preparing status summaries for deal team leads. By handling this layer, VAs allow the BD professional to focus their attention on the evaluative judgments that require domain expertise.
For large pharma organizations running multiple simultaneous due diligence processes, VA teams can be assigned per-deal, providing dedicated operational support without the cost or time required to hire additional BD coordinators.
Conference Strategy and Partnering Logistics
Pharmaceutical BD calendars are defined by a handful of major partnering events: JP Morgan Healthcare Conference, BIO International, ASCO, and a rotating calendar of therapeutic-area conferences. Each event requires substantial preparation: partnering platform registration, meeting request prioritization, pre-meeting dossier preparation, and post-conference follow-through.
VAs can handle the end-to-end conference operations cycle. Before the event, they research registered companies, prioritize meeting targets against BD strategy, and manage the partnering platform calendar. During the conference, they can serve as a remote logistics hub — sending briefing reminders and tracking meeting completions. After the event, they manage follow-up outreach, update CRM records, and track next steps from each meeting.
Competitive Intelligence and Market Monitoring
Staying current on competitor licensing activity, clinical trial readouts, and M&A transactions is foundational to pharma BD strategy. But manual tracking of FDA submissions, SEC filings, clinical trial databases, and industry press is time-consuming at scale.
VAs can maintain curated competitive intelligence feeds using structured monitoring tools, flagging relevant developments for BD team review on a daily or weekly cadence. This keeps BD professionals informed without requiring them to personally scan dozens of information sources.
For pharma business development companies looking to increase deal velocity and reduce the operational drag that slows BD teams, Stealth Agents provides experienced virtual assistants with pharmaceutical industry knowledge across the full BD lifecycle.
Sources
- EvaluatePharma, World Preview 2028: Embracing the Patent Cliff
- Deloitte, 2023 Global Life Sciences Outlook
- U.S. National Library of Medicine, ClinicalTrials.gov Database